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Abstract The human LDL receptor (LDLR) has a binding do-
main which consists of seven contiguous ligand-binding (LB) re-
peats, each -40 amino acids long with three disulfide bonds. The 
second LB repeat, which is required for full binding of LDL, has 
been expressed, purified and folded to yield a single, fully oxidized 
isomer. By selective reduction and alkylation, we have shown that 
the cysteine residues have a I-III, II-V, IV-VI connectivity, 
matching that recently determined for the amino-terminal repeat. 
We suggest that the first two LB repeats of the LDLR, with their 
unique disulfide-bonding pattern, serve as a structural paradigm 
for other LB repeats. 
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1. Introduction 
The LDL receptor (LDLR) is the prototype of a family of 
cell surface receptors which mediate the endocytosis of multiple 
ligands [1]. These receptors share a group of common structural 
elements, which include cysteine-rich ligand-binding (LB) or 
complement repeats [I]. The LDLR has a binding domain 
which consists of seven contiguous LB repeats, each -40 amino 
acids long [2]. with a repeating pattern of six cysteine residues 
and a highly conserved series of negatively charged amino acids 
near the COOH-terminus. The LDLR utilizes these repeats to 
bind plasma lipoproteins that contain apolipoprotein (apo) 
B-IOO [3] and apoE [4]. Binding is believed to involve iOlliC 
interactions between acidic residues in the repeats and clusters 
of basic ammo acids in apoB-IOO and apoE [2]. LB repeats are 
not restncted to the LDL receptor family of cell surface recep-
tors. but are found in diverse proteins, including complement 
factors [5]. the proteoglycan perlecan [6], a receptor for sub-
group A Rous Sarcoma ViruS [7] and the linker chain of the 
hemoglobin of Lumbricus terrestris [8]. 
As a first step towards understanding the structure and func-
tion of LB repeats, we have recently expressed the amino-
terminal repeat (rLBI) of the LDLR and determined its disul-
fide connectivity (S. Bieri. unpubJ. obs.) and 3-dimensional 
structure [9]. This repeat was chosen because of the availability 
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recombmant LBI (LB2): RP. reverse-phase. TCEP, Tns-(2-carboxy-
ethyl)-phosph1Oe: AM. acetamide: PE, pyridylethyl: AMn-rLB2. rLB2 
with n acetamide-labelled cysteine residues; AM/PEI6 _n,-rLB2. rLB2 
with n acetamlde- and (6-n) pyndylethyl-labelled cysteine residues. 
of a conformation-specific monoclonal antibody (lgG-C7) 
which provided a means of analysing the conformation of the 
expressed and folded repeat [10]. rLBI folded into a single 
isomer with three unique disulfide bonds. connecting Cys(l)-
Cys(III), Cys(II)-Cys(V) and Cys(IV)-Cys(VI)I. However. 
LBI is unique amongst the LB repeats. in that it is not required 
for ligand-binding. To determine whether the unique disulfide-
bonding pattern described for rLB I is conserved in other LB 
repeats, we have extended our studies to the expression. folding 
and disulfide-bonding pattern for the second LB repeat, LB2. 
We chose this repeat because it plays a role in the binding of 
apoB-IOO [11.12]. Patients with a splicing defect, which leads 
to the deletion of the exon which encodes LB2, develop a severe 
clinical phenotype of familial hypercholesterolemia. which has 
been attributed in part to a reduced affinity of the mutant 
receptor for LDL [13]. 
2. Materials and methods 
V1Oylpyrid1Oe. bovine thrombin. IOdoacetamide, GSH-agarose and 
sequencing-grade trypsm were obtamed from Sigma. Tns-(2-car-
boxyethyl)-phosph1Oe (TCEP) was kindly prOVided by Alun Jones 
(University of Queensland). Other chemicals used were reagent grade. 
21 ExpressIOn. joldmg and purificatIOn oj rLB2 
The cDNA-encoding LB2 (reSidues 43-83 of the mature LDLR) was 
PCR-amplified using pnmers which contained EcoRI and BamHI sites 
(primer I: GAGGGATCCTTGTCTGTCACCTGC; pnmer 2: CC-
GAATTCTCAACAGCCTTGCTCGTCTGA), digested with EcuRI 
and BamHI and cloned 1Oto the expression vector pGEX-2T, to give 
pGST-LB2. Recombinant LB2 (rLB2) was expressed in E coli DH5a 
using a 15-1 Chemap fermenter (Chemap. Miinnedorf, Switzerland) and 
was punfied as prevIOusly described [14]. rLB2 (250-400.ug/ml) was 
folded overmght in presence of 3 mM GSH/0.3 mM GSSG in 50 mM 
Tris-HC1, 150 mM NaCI. 2.5 mM CaCl" pH 8.5, at 4°C, and was 
punfied us10g an Econosil CI8 reverse-phase HPLC column (lO-.um 
partIcle SIZe, 60-A pore. 10 x 250 mm; Alltech. Deerfield. IL). A tri-
fluoroacetlc aCid/acetonItrile solvent system (solvent A: 0.1 % tri-
fluoroacetlc acid 10 water: solvent B: 0.1 % trifluoroacetic aCid 10 ace-
tOnItnle) was used for the punficatlOn, tYPically With a flow rate of 2.5 
mllmm. FPLC analyses were performed on a Smart System (AMRAD-
Pharmacla. Australia), us10g a .uRPC C2/C18 reverse-phase column 
(3-.um particle size. 120-A pore. 2.1 x 100 mm) With a trifluoroacetlC 
acid/acetonItrIle buffer system (see above). 
2.:3 Reductwn and alkylation ll'lth wdoacetamide 
Partial reduction and alkylatIOn of rLB2 was performed as previ-
ously described [15], Bnefly, HPLC-purified rLB2 (2.ug 10 15-25.ul of 
elution buffer) was mixed wah an equal volume of 20 mM Tns-
(2-carboxyethyl)-phosph1Oe (TCEP) 10 20 mM ammOnIum carbonate. 
pH 3. and 10cubated for 7-10 min at 10°C The partially reduced 
peptIde was Immediately alkylated With supersaturated IOdoacetamide 
(- 2.2 M). quenched - 25 s later with 200.u1 ofO,5 M citric aCid and 10Jected 
1 Cysteme residues IdentIfied with Roman numerals (Cys(l) through 
Cys(VI)) refer to the order of cysteme residues and not their absolute 
pOSitIOn, 
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onto a RP-FPLC column. Different alkylated forms of rLB2 (AM,,-
rLB2). where n corresponds to the number of acetamide (AM) groups 
incorporated, were separated uSing a 24-36% acetonitrile gradient over 
24 min. 
2.3. ReductIOn and alkylation H'lth l'mylpyridine 
AM,,-rLB2 (0.5 /1g in 50-100/11 of FPLC elution buffer) was incu-
bated with 100/11 of 0.5 M Tris acetate, pH 8, 2 mM Na2EDTA, 20 mM 
DTT, at 65°C for 15 min. FollOWing addition of 5 /11 of 4-vinylpyridine, 
the reaction mixture was Incubated in the dark, at room temperature, 
for 20 min. The reaction was stopped by adding 100/11 of 0.5 M citrIC 
acid. ThIS resulted in the formation of rLB2 which was labelled with 
both AM and pyridylethyl (PE) groups (AM)PE(6'n)-rLB2) The pep-
tide was purified by RP-FPLC uSing a 24-36% acetonitrile gradient 
over 24 min. 
24. TrJPtic digestion of AMIPE-labelled rLB2 
PeptIde (2-5 /1g) was taken to dryness In a Savant SpeedVac SCIOO, 
dissolved In 100/11 of 50 mM NH4HCO J, pH 8.5, containing 2 mM 
CaCI2 and cleaved with trypsin using a I: 10 (w/w) ratio of enzyme 
to protein, for 16 h at 37°C. TryptIc fragments were separated by 
RP-FPLC uSing a 1-30% acetonItrIle gradient over 60 min and indivi-
dual peaks collected. 
2.5 Mass spectrometry and ammo acid sequence analYSIS 
Peptldes were analysed using a triple quadrupole mass spectrometer 
(SCIEX API III, Thornhill, Canada), equipped with an IOnspray inter-
face and operated in the posItIve detection mode. Data were analysed 
using SCIEX software (MacSpec verSIOn 3.2). Peptides (0.1-1.0 nmol) 
were sequenced USIng automated Edman degradation on an Applied 
BID systems 470A protein gas-phase sequencer WIth on-lIne PTH analy-
SIS 
3. Results and discussion 
LB2 was expressed as a thrombin-cleavable GST fusion pro-
tein in E. coli, using the expression vector pGST-LB2 as de-
scribed in Section 2. The fusion protein was bound to GSH-
agarose and cleaved with thrombin to release the 43 amino acid 
peptide rLB2: 
43 53 63 73 83 
GSLSVTCKSGDFSCGGRVNRCIPQFWCDGQVDCDNGSDEQGC 
The first two amino acids of this peptide (GS) are derived from 
the thrombin cleavage site [14] and are followed by residues 
43-83 of the mature LDL receptor. The peptide was folded in 
Table I 
AnalYSIS of pep tides formed from partIal reduction and alkylatIOn of 
rLB2d 
Peptideb M, n' 
1 4932 6 
2 4816 4 
3 4582 0 
4 4816 4 
5 4816 4 
6 4701 2 
7 4700 2 
dpeptides were produced by partial reduction and alkylation of rLB2, 
purified by RP-FPLC as described In Fig 2 and were analysed by mass 
spectrometry. 
bpeptide numbers correspond to peaks in FIg. 2. Peptide peaks were 
combined from several RP-FPLC runs. 
'The number of alkylated cysteine reSIdues (N) In each of the Isolated 
components was calculated using M, = 4582 for the completely oxi-
dized peptide (peptide 3) and a mass of 58 Da for the AM group. 
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FIg I. RP-FPLC analYSIS of rLB2 follOWIng thiol-disulfide exchange. 
A 10-40% acetonitrIle gradIent over 30 min was used. Inset: mass 
spectral analysis of rLB2 following incubation In 6 M GnHCI (2 h at 
50°C) and Injection into 2.2 M iodoacetamlde. The treated peptIde was 
immediately purified by RP-FPLC and analysed by mass spectrometry. 
the presence of a GSH/GSSG redox buffer at 4°C for at least 
12 h, to yield a form which eluted as a single peak from a 
RP-FPLC column (Fig. 1), consistent with the presence of a 
single isomer. This isomer was purified by preparative RP-
HPLC. Folded and RP-HPLC-purified rLB2 was used for all 
subsequent studies described below. 
Mass spectral analysis of refolded rLB2 gave a molecular 
mass of 4582 ± 1 mass unit. consistent with the presence of 3 
disulfide bridges. Calculated values for reduced and fully oxi-
dized forms of rLB2 are 4588 and 4582. To confirm the com-
plete absence of free cysteine-thiol groups, rLB2 was incubated 
in the presence of 6 M GnHCI for 2 h at 50°C and was rapidly 
injected into a supersaturated solution of iodoacetamide to 
alkylate any free thiol groups. Subsequent mass spectral analy-
sis of the peptide showed that its molecular mass was un-
changed, with no evidence for species with alkylated cysteine 
residues (Fig. I, inset). To confirm that cysteine residues could 
be completely alkylated under these conditions, rLB2 was re-
duced with 45 mM DTT prior to the denaturation and alkyla-
tion reactions. This resulted in a molecular mass of 4931 ± I, 
consistent with a calculated mass of 4930 for rLB2 with 6 
alkylated cysteine residues (data not shown). We conclude that 
the refolded rLB2 domain is completely oxidized and contains 
no free cysteine thiol groups. 
The traditional strategy for analysing disulfide connectivities 
is to cleave the peptide chain with proteolytic enzymes and to 
isolate bridged fragments for amino acid analysis. This ap-
proach is often unsuccessful for peptides which contain multi-
ple disulfide bonds [15]. Indeed, both rLBI and rLB2 are resis-
tant to cleavage by trypsin. We used an alternative method in 
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which disulfide bonds are sequentially reduced at acidic pH 
with organic phosphines followed by rapid alkylation of result-
ing free'thlol groups with iodoacetamide [15]. In this work we 
reduced rLB2 with TCEP at pH 3. The abundance of individual 
reduced peptides formed depended on the temperature and 
time of the TCEP reaction. For rLB2, reduction at 10°C for 
7 10 mill resulted in a significant depletion of fully oxidized 
rLB2 and minimized the formation of fully reduced rLB2. 
RP-FPLC (Fig. 2) and mass spectral analysis (Table 1) of par-
tlally reduced and AM-labelled rLB2 lead to the identification 
of 7 species, out of a total of 8 theoretically possible species. 
Molecular masses of peptides 1-7 (denved from peaks 1-7 in 
Fig. 2) were consistent with species which contained 0, 2, 4 or 
6 AM groups (Table 1), derived from peptides in which 0, I, 
2 or 3 disulfide bonds were reduced, respectively. Peak 7 always 
had a shoulder ("S' in Fig. 2), suggesting that this might contain 
the 'missing' 8th peptide. Since this peptide, like pep tides 6 and 
7, was predicted to contain two acetamide groups, mass spec-
tral analysIs could not be used to confirm its presence directly. 
To identify a single disulfide bond uniquely, partially reduced 
peptides are reqUIred in which either a single disulfide bond has 
been reduced, or in which a single disulfide bond remains. 
Because the most promment peaks which contain such peptides 
are peaks 4 and 7, the corresponding peptides were used for 
subsequent analysis. Peptide 7 (AM2-rLB2) was isolated, taking 
care to avoid material in the shoulder fraction, and was reduced 
III the presence of DTT. Free cysteine thiol groups were al-
kylated with 4-vinylpyridine to yield the doubly labelled peptide 
AM/PE4-rLB2. Amino acid sequence analysis of residues 1-22 
of thiS peptide showed that both Cys(I) and Cys(III) were 
AM-labelled, while Cys(II) was PE-labelled. Since peptide 7 
contained only two AM-labelled cysteine residues, we conclude 
that these cysteine residues were disulfide linked in the fully 
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Fig. 2. RP-FPLC separatIOn of partially reduced and alkylated rLB2. 
Disulfide bonds were partially reduced With TCEP (10 mm, IOOC) and 
the resultmg free thiols alkylated by mJection into 22M IOdoacetamlde 
Resultmg peptIdes were separated by RP-FPLC, usmg a linear (24-
36%) gradient of acetonitrile 
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Fig. 3. RP-FPLC separatIOn of a tryptic digest of PE-Iabelled peptide 
7. Peptide 7 was reduced ",ith DTT and alkylated With vmylpyridme 
to yield the doubly labelled peptide AM,/PE4-rLB2. This peptide was 
digested With trypsin (1:10 w/w) for 16 h at 37°C Cleavage products 
were separated by RP-FPLC usmg a 1- 30% acetonitrile gradient over 
60 mm. 
oxidized peptide. These data therefore provide direct evidence 
for a Cys(I)-Cys(III) disulfide bridge. 
Peptide 4 (AM4-rLB2) was isolated by collecting only half of 
peak 4 (Fig. 2) in order to millimize contamination by peptide 
3 (fully oxidized rLB2). The two cysteine residues in the remain-
ing disulfide bond were labelled with vinylpyridine, following 
reduction with DTT. The resulting AMjPE2-rLB2 was cleaved 
with trypsin and cleavage products separated by RP-FPLC 
(Fig. 3). The locations of tryptic sites (K8, R 17, R20 and R27) 
relative to Cys residues, together with the predicted masses of 
tryptic fragments, are illustrated in Fig. 4. Mass spectral analy-
sis showed that major fragments were derived from PE2-
labelled peptide-4 (black boxes in Fig. 4), in which both 
rlB2 N 
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Fig. 4. Identification of peptIdes formed by tryptic digestIOn of AM,I 
PE4-rLB2. A schematic representatIOn of rLB2, Its tryptIC cleavage sItes 
(arrows) and the locatIOn of cysteme reSidues reialive to these sites IS 
shown at the top of the figure. The molecular masses of each of the 
unmodified tryptic peptldes, as well as the predicted masses for all 
combinations of AM/PE-modlfied fragments, are shown below the 
representation of the tryptIC peptldes. Molecular masses for tryptic 
fragments of peptide 4 are shown in black boxc" while the gray b(ne, 
represent cleavage products of peptIde 3 
344 
\ 
COOH 
Fig. 5. Structural model for rLB2, which Illustrates the trIcyclic ,truc-
ture of the disulfide bridged peptide The locatIOn of tryptic cleavage 
sites is indicated by thin hnes. 
PE-Iabelled cysteine residues were located in a single fragment 
comprising Cys(lV)-Cys(VI). However, fragments derived 
from peptide 3 (PE6-rLB2 from peak 3 in Fig. 2) were present 
as minor contaminants (gray boxes in Fig. 4). Indeed, all but 
one of the predicted fragments derived from peptide 3 were 
identified. Given the fact that peaks 3 and 4 overlap signifi-
cantly, the presence of these fragments was not unexpected. 
The Mr = 1912 fragment (residues 28-43) which contained 
Cys(IV), Cys(V) and Cys(VI), was isolated by RP-FPLC 
chromatography and sequenced. Analysis of the first 8 residues 
of this fragment (C28-C43) showed that there was minor con-
tamination from the Mr = 851 (residues GI-K8) and Mr = 988 
fragments (S9-R 17) derived from peaks which flank the 
Mr = 1912 peak. However, the assignment of residues C28-
D35, and m particular the demonstration that Cys(IV) was 
labelled with a PE group, and that Cys(V) was labelled with an 
AM group, was unequivocal. Since the Cys(IV)-Cys(VI) frag-
ment contained two PE-Iabelled cysteine residues, we conclude 
that Cys(VI) was also PE-Iabelled and that the two PE-Iabelled 
cysteine residues (Cys(IV) and Cys(VI) were disulfide-bonded 
prior to reduction and pyridylethylatlOn of peptide 4. [n view 
of the Cys(I)-Cys(III) and Cys(lV)-Cys(VI) connectivities, we 
infer that the remaining disulfide bond bridges Cys( II) and 
Cys(V). The tricyclic structure of rLB2 formed by these over-
lapping disulfide bonds is illustrated in Fig. 5. 
The Cys(l)-Cys(III), Cys(lI)-Cys(V), Cys(IV)-Cys(V[) con-
nectivity is identical with that found for rLBI (S. Bieri et al., 
unpubl. obs.; [9]). We conclude that the same arrangement of 
disulfide bonds results in thermodynamically favored struc-
tures for both rLBI and rLB2. For rLBI the resulting structure 
is immunologically indistinguishable from the same repeat in 
the LDLR (S. Bieri et aI., unpub!. obs.; [9]). Although there are 
no corresponding antibodies for LB2, the fact that it folds into 
a smgle isomer with a disulfide-bonding pattern which is iden-
tical with that of rLBI, strongly suggests that this pattern is a 
general feature of LB repeats. 
The 3-dimensional structure of rLB I contams a ,B-hairpin 
S Bien et al / FEBS Letters 371 (1995) 341-344 
following a series of turns [9]. This results in a structure in 
which most of the acidic residues, including 1h~ highly con-
served SDE triad, are clustered on one face of the molecule, 
formmg an appropriate charged surface for interaction with 
basic residues of apoB-1 00 and apoE. A similar clustering of 
charged residues is present in rLB2 (N. Daly et aI., unpubl. 
obs.). Despite the apparent structural similarity, LB I plays no 
role in the binding of ligands, while LB2 does. Experimentally, 
one of the major differences between rLB I and rLB2 is the 
susceptibility to TCEP- mediated reduction. While a tempera-
ture of 65°C was used for he partial reduction of rLB I (S. Bieri 
et al., unpub!. obs.), a much lower temperature of lOoC was 
reqUired for rLB2. We surmise that this is due to a more flexible 
structure for rLB2, which allows the TCEP molecules greater 
access to the disulfide bonds. This is supported by CH]NMR 
spectroscopic studies, which show that rLB2 is much more 
flexible than rLBI (N. Daly et a!., unpub!. obs.). It is possible 
that the greater flexibility of LB repeats IS required to allow 
aCidic residues to acquire an appropriate conformation for their 
interaction with clusters of basic residues on apoB-IOO and 
apoE. Alternatively, specific interactions between different LB 
repeats may be required to place them in an appropriate envi-
ronment which allow interactions with either apoB-IOO or 
apoE. Such interactions may depend on a structural element 
not present in LB I. 
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